查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1824315

2025年治療診斷學全球市場報告

Theranostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年，治療診斷學市場將快速成長，到2029年將達到1,849.4億美元，複合年成長率為10.7%。預測期內的成長可歸因於對精準醫療日益成長的關注、腫瘤學、人口老齡化和慢性病領域之外的應用擴展、生物標記發現的進步以及政府的支持和資金籌措。預測期內的主要趨勢包括監管支持、伴隨診斷的興起、對癌症的關注度增加、意識提升以及技術融合。

未來五年10.7%的成長率預測比我們先前的預測略有下降0.2%。這一下降主要源自於美國與其他國家之間關稅的影響。徵收關稅可能會擾亂美國醫療供應鏈，增加從比利時和澳洲進口的鎦-177前列腺特異性膜抗原放射性配體的成本，從而可能危及靶向癌症治療，並增加核醫學領域的費用。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，其影響也將更加廣泛。

預計治療診斷學市場的成長將受到癌症盛行率上升的推動。癌症的特徵是細胞不受控制地增殖，影響各個器官，是全球發病率和死亡率的重要原因。治療診斷學整合了治療和診斷，在癌症和慢性病的管理方面具有巨大潛力。透過結合診斷和治療能力，這種方法可以促進個人化、標靶治療，並推動醫療保健領域的創新。因此，癌症患者數量的增加將有助於治療診斷學市場的擴張。例如，截至 2022 年 1 月，美國國家癌症美國(NCI) 報告稱，美國約有 5.4% 的人口（即 1,810 萬人）是癌症倖存者。此外，2022 年有 623,405 人患有轉移性乳腺癌、前列腺癌、肺癌、大腸直腸癌、乳癌癌和轉移性黑色素瘤，預計到 2025 年這一數字將增加到 693,452。因此，癌症盛行率的上升是治療診斷學市場的主要驅動力。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 治療診斷學 Global：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球治療診斷學市場：成長率分析
  • 全球治療診斷學市場表現：規模與成長，2019-2024
  • 全球治療診斷學市場預測：規模與成長，2024-2029 年，2034 年
  • 全球治療診斷學：總目標市場（TAM）

第6章 市場細分

  • 全球治療診斷學市場：依疾病類型、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 神經系統疾病
  • 心血管疾病
  • 免疫疾病
  • 腫瘤疾病
  • 其他疾病
  • 全球治療診斷學市場：依技術、績效與預測，2019-2024 年、2024-2029 年、2034 年
  • 聚合酵素鏈鎖反應
  • 免疫組織化學
  • 原位雜合技術
  • 定序
  • 其他技術
  • 全球治療診斷學市場：按最終用戶、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院和診所
  • 診斷實驗室
  • 其他最終用戶
  • 全球治療診斷學市場：依神經系統疾病（類型）細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 阿茲海默症
  • 帕金森氏症
  • 多發性硬化症
  • 癲癇
  • 其他神經系統疾病
  • 全球治療診斷學市場：依心血管疾病類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 冠狀動脈疾病
  • 心臟衰竭
  • 心房顫動
  • 高血壓
  • 其他心血管疾病
  • 全球治療診斷學市場：依免疫疾病類型細分，實質及預測，2019-2024 年、2024-2029 年、2034 年
  • 類風濕性關節炎
  • 全身性紅斑性狼瘡
  • 發炎性腸道疾病
  • 銀屑病
  • 其他免疫疾病
  • 全球治療診斷學市場：依腫瘤疾病類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 其他腫瘤疾病
  • 全球治療診斷學市場：依疾病類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 感染疾病
  • 代謝紊亂
  • 遺傳性疾病
  • 其他疾病

第7章 區域和國家分析

  • 全球治療診斷學市場：區域表現及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 全球治療診斷學市場：依國家、表現及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 治療診斷學市場：競爭格局
  • 治療診斷學市場：公司簡介
    • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • AmeriPath Inc Overview, Products and Services, Strategy and Financial Analysis
    • Beckman Coulter Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Astellas Pharma
  • Helmholtz Centre for Infection Research
  • Radiopharm Theranostics Ltd
  • Alpha-Theranostics
  • UNIVERZITET U NOVOM SADU
  • Cardio-Theranostics LLC
  • Curium
  • SoFi Technologies Inc.
  • Theradiag
  • Cell Theranostics
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc
  • Qiagen NV
  • Foundation Medicine Inc
  • Leica Biosystems Nussloch GmBH

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029 年治療診斷學市場：提供新機會的國家
  • 2029 年治療診斷學市場：細分領域帶來新機會
  • 2029 年治療診斷學市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r24554u

Theranostics is a medical discipline that integrates therapeutics and diagnostics into a unified approach. It entails the development and application of diagnostic tests that not only identify diseases or conditions but also furnish information for guiding personalized therapeutic interventions.

Various types of theranostics are categorized by disease type, encompassing neurological disorders, cardiovascular diseases, immunological disorders, oncology diseases, and others. Neurological disorders comprise a spectrum of conditions affecting the brain, spinal cord, and nerves, leading to diverse symptoms and impairments. Theranostics plays a crucial role in ensuring precise diagnosis, monitoring disease progression, and guiding personalized treatment strategies for these disorders. The technologies employed for theranostics encompass polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others. These technologies find application across different end-users, including hospitals and clinics, diagnostic laboratories, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The theranostics market research report is one of a series of new reports from The Business Research Company that provides theranostics market statistics, including the theranostics industry's global market size, regional shares, competitors with a theranostics market share, detailed theranostics market segments, market trends and opportunities, and any further data you may need to thrive in the theranostics industry. This theranostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The theranostics market size has grown rapidly in recent years. It will grow from $111.1 billion in 2024 to $122.98 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to advancements in molecular imaging, shift to value-based healthcare, integration in oncology.

The theranostics market size is expected to see rapid growth in the next few years. It will grow to $184.94 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to rise in precision medicine initiatives, expanding applications beyond oncology, population aging and chronic diseases, advancements in biomarker discovery, government support and funding. Major trends in the forecast period include regulatory support, rise of companion diagnostics, increased focus on cancer theranostics, patient engagement and awareness, technological convergence.

The forecast of 10.7% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical supply chains by increasing costs for lutetium-177 Prostate-Specific Membrane Antigen theranostic radioligands imported from Belgium and Australia, potentially compromising targeted cancer therapy and raising nuclear medicine department expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth of the theranostics market is expected to be driven by the increasing prevalence of cancer. Cancer, characterized by uncontrolled cell growth affecting various organs, remains a significant source of morbidity and mortality globally. Theranostics, integrating therapeutics and diagnostics, holds substantial promise in cancer and chronic disease management. This approach facilitates personalized and targeted treatments by combining diagnostic and therapeutic capabilities, fostering innovation in the healthcare sector. Consequently, the rise in the number of cancer patients is poised to contribute to the expansion of the theranostics market. For instance, as of January 2022, the National Cancer Institute (NCI) reported that approximately 5.4% of the U.S. population, equivalent to 18.1 million individuals, are cancer survivors. Furthermore, there were 623,405 people living with metastatic breast, prostate, lung, colorectal, or bladder cancer, or metastatic melanoma in 2022, with projections indicating an increase to 693,452 by 2025. Thus, the increasing prevalence of cancer is a key driver for the theranostics market.

The expected growth of the theranostics market is also anticipated to be fueled by the growing investment in research and development. Research and development (R&D) constitute a series of activities conducted by individuals, universities, corporations, and governments to discover new knowledge, create new products or processes, or enhance existing ones. In the realm of theranostics, R&D efforts aim to deliver both imaging and therapeutic agents specifically to diseased tissues, minimizing side effects and maximizing therapeutic efficacy. For instance, in April 2023, the National Cancer Institute (NCI) allocated $437,000 in funds to explore the function of enolase in theranostics, a burgeoning field that synergizes therapy and imaging to molecularly target and eliminate cancer cells while preserving healthy tissue. Thus, the increasing investment in research and development serves as a driving force for the theranostics market.

Major companies in the theranostics market are concentrating on developing advanced solutions, such as theranostics clinical trials, to enhance personalized medicine and improve patient outcomes by integrating diagnostics and therapeutics into a unified treatment approach. Theranostics clinical trials are research studies designed to assess the combined use of diagnostic tests and targeted therapies, tailoring treatment strategies to individual patients. These trials focus on evaluating the effectiveness of specific treatments based on patient-specific biomarkers, thereby advancing personalized medicine. For example, in May 2024, BAMF Health, a cancer treatment center based in the U.S., launched the COMBAT Trial, formally titled "A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617" (NCT05633160). This trial features a rapid activation process facilitated by BAMF Health's BAMF RapAct program, allowing it to launch in just seven weeks. It also emphasizes the use of innovative radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR), with the goal of improving treatment options for patients with limited therapeutic alternatives.

Major companies in the theranostics market are concentrating on the development of innovative products, including molecular targeted radiopharmaceuticals (MTRP), to gain a competitive advantage. Molecular targeted radiopharmaceuticals are radioactive drugs used for diagnosing and treating diseases, particularly cancer. An example is the launch of 177Lu(n.c.a.)-PSMA-Therapy by Applied Molecular Therapeutics, a US-based biopharmaceutical company, in February 2022. This MTRP specifically targets the PSMA (prostate-specific membrane antigen) protein on the surface of prostate cancer cells, delivering a high radiation dose directly to the tumor while minimizing damage to healthy tissue. The radioactive 177Lu emitted by the therapy kills the cancer cells after binding to the PSMA protein.

In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company specializing in radiopharmaceutical products, acquired Pharma15 Corporation for $4 million. This strategic acquisition positions Radiopharm to explore next-generation radiopharmaceuticals' potential for treating prostate cancer, surpassing PSMA-based therapies, and advancing innovative solutions for patients. Pharma15 Corporation, a US-based pharmaceutical company, specializes in developing radio-immuno-theranostic platforms and pharmaceutical products.

Major companies operating in the theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc, Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Helmholtz Centre for Infection Research, Radiopharm Theranostics Ltd, Alpha- Theranostics, UNIVERZITET U NOVOM SADU, Cardio-Theranostics LLC, Curium, SoFi Technologies Inc., Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc, Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, The Bristol-Myers Squibb Company, Danaher Corporation, MilliporeSigma, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

North America was the largest region in the global theranostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the theranostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The theranostics market consists of revenues earned by entities by providing genetic testing, targeted therapy services, contract development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The theranostics market also includes of sales of companion diagnostics, nanomedicine and 2D nano-theranostics materials. Values in this market are ""factory gate"" values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Theranostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on theranostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for theranostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The theranostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Disease Type: Neurological Disorders; Cardiovascular Diseases; Immunological Disorders; Oncology Diseases; Other Diseases
  • 2) By Technology: Polymerase Chain Reaction; Immunohistochemistry; In-Situ Hybridization; Sequencing; Other Technologies
  • 3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users
  • Subsegments:
  • 1) By Neurological Disorders: Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Epilepsy; Other Neurological Disorders
  • 2) By Cardiovascular Diseases: Coronary Artery Disease; Heart Failure; Atrial Fibrillation; Hypertension; Other Cardiovascular Diseases
  • 3) By Immunological Disorders: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Psoriasis; Other Immunological Disorders
  • 4) By Oncology Diseases: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Oncology Diseases
  • 5) By Other Diseases: Infectious Diseases; Metabolic Disorders; Genetic Disorders; Other Diseases
  • Companies Mentioned: Abbott Laboratories; Agilent Technologies Inc.; AmeriPath Inc; Beckman Coulter Inc.; Thermo Fisher Scientific Inc; Astellas Pharma; Helmholtz Centre for Infection Research; Radiopharm Theranostics Ltd; Alpha- Theranostics; UNIVERZITET U NOVOM SADU; Cardio-Theranostics LLC; Curium; SoFi Technologies Inc.; Theradiag; Cell Theranostics; F. Hoffmann-La Roche AG; GE HealthCare Technologies Inc; Qiagen NV; Foundation Medicine Inc; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Siemens Healthineers; Advanced Accelerator Applications; AstraZeneca plc; Bayer AG; Bio-Rad Laboratories; The Bristol-Myers Squibb Company; Danaher Corporation; MilliporeSigma; Illumina Inc.; Merck KGaA; Roche Diagnostics Corporation; PerkinElmer Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Theranostics Market Characteristics

3. Theranostics Market Trends And Strategies

4. Theranostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Theranostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Theranostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Theranostics Market Growth Rate Analysis
  • 5.4. Global Theranostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Theranostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Theranostics Total Addressable Market (TAM)

6. Theranostics Market Segmentation

  • 6.1. Global Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Neurological Disorders
  • Cardiovascular Diseases
  • Immunological Disorders
  • Oncology Diseases
  • Other Diseases
  • 6.2. Global Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction
  • Immunohistochemistry
  • In-Situ Hybridization
  • Sequencing
  • Other Technologies
  • 6.3. Global Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Other End Users
  • 6.4. Global Theranostics Market, Sub-Segmentation Of Neurological Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Other Neurological Disorders
  • 6.5. Global Theranostics Market, Sub-Segmentation Of Cardiovascular Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Coronary Artery Disease
  • Heart Failure
  • Atrial Fibrillation
  • Hypertension
  • Other Cardiovascular Diseases
  • 6.6. Global Theranostics Market, Sub-Segmentation Of Immunological Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Inflammatory Bowel Disease
  • Psoriasis
  • Other Immunological Disorders
  • 6.7. Global Theranostics Market, Sub-Segmentation Of Oncology Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Other Oncology Diseases
  • 6.8. Global Theranostics Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Infectious Diseases
  • Metabolic Disorders
  • Genetic Disorders
  • Other Diseases

7. Theranostics Market Regional And Country Analysis

  • 7.1. Global Theranostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Theranostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Theranostics Market

  • 8.1. Asia-Pacific Theranostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Theranostics Market

  • 9.1. China Theranostics Market Overview
  • 9.2. China Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Theranostics Market

  • 10.1. India Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Theranostics Market

  • 11.1. Japan Theranostics Market Overview
  • 11.2. Japan Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Theranostics Market

  • 12.1. Australia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Theranostics Market

  • 13.1. Indonesia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Theranostics Market

  • 14.1. South Korea Theranostics Market Overview
  • 14.2. South Korea Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Theranostics Market

  • 15.1. Western Europe Theranostics Market Overview
  • 15.2. Western Europe Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Theranostics Market

  • 16.1. UK Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Theranostics Market

  • 17.1. Germany Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Theranostics Market

  • 18.1. France Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Theranostics Market

  • 19.1. Italy Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Theranostics Market

  • 20.1. Spain Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Theranostics Market

  • 21.1. Eastern Europe Theranostics Market Overview
  • 21.2. Eastern Europe Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Theranostics Market

  • 22.1. Russia Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Theranostics Market

  • 23.1. North America Theranostics Market Overview
  • 23.2. North America Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Theranostics Market

  • 24.1. USA Theranostics Market Overview
  • 24.2. USA Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Theranostics Market

  • 25.1. Canada Theranostics Market Overview
  • 25.2. Canada Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Theranostics Market

  • 26.1. South America Theranostics Market Overview
  • 26.2. South America Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Theranostics Market

  • 27.1. Brazil Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Theranostics Market

  • 28.1. Middle East Theranostics Market Overview
  • 28.2. Middle East Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Theranostics Market

  • 29.1. Africa Theranostics Market Overview
  • 29.2. Africa Theranostics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Theranostics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Theranostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Theranostics Market Competitive Landscape And Company Profiles

  • 30.1. Theranostics Market Competitive Landscape
  • 30.2. Theranostics Market Company Profiles
    • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AmeriPath Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Beckman Coulter Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis

31. Theranostics Market Other Major And Innovative Companies

  • 31.1. Astellas Pharma
  • 31.2. Helmholtz Centre for Infection Research
  • 31.3. Radiopharm Theranostics Ltd
  • 31.4. Alpha- Theranostics
  • 31.5. UNIVERZITET U NOVOM SADU
  • 31.6. Cardio-Theranostics LLC
  • 31.7. Curium
  • 31.8. SoFi Technologies Inc.
  • 31.9. Theradiag
  • 31.10. Cell Theranostics
  • 31.11. F. Hoffmann-La Roche AG
  • 31.12. GE HealthCare Technologies Inc
  • 31.13. Qiagen NV
  • 31.14. Foundation Medicine Inc
  • 31.15. Leica Biosystems Nussloch GmBH

32. Global Theranostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Theranostics Market

34. Recent Developments In The Theranostics Market

35. Theranostics Market High Potential Countries, Segments and Strategies

  • 35.1 Theranostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Theranostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Theranostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer